Quince Therapeutics Inc (QNCX)

Currency in USD
1.070
+0.075(+7.54%)
Closed·
1.0700.000(0.00%)
·
QNCX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.9601.110
52 wk Range
0.79045.499
Key Statistics
Prev. Close
0.995
Open
1.04
Day's Range
0.96-1.11
52 wk Range
0.79-45.499
Volume
1.83M
Average Volume (3m)
6.05M
1-Year Change
-89.5098%
Book Value / Share
2.81
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QNCX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
0.000
Downside
-100.00%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Quince Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

0 Buy
3 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 0.000
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Maxim Group
Hold---DowngradeJan 30, 2026
Lucid Capital Markets
Sell--8.00DowngradeJan 30, 2026
D. Boral Capital
Hold---DowngradeJan 30, 2026
Citizens
Hold---DowngradeJan 30, 2026
Citizens
Buy8.00+647.66%-MaintainJan 22, 2026

Earnings

Latest Release
May 19, 2026
EPS / Forecast
-- / -0.16
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

QNCX Income Statement

Compare QNCX to Peers and Sector

Metrics to compare
QNCX
Peers
Sector
Relationship
P/E Ratio
−0.5x−3.1x−0.5x
PEG Ratio
−0.01−0.030.00
Price/Book
1.1x2.4x2.6x
Price / LTM Sales
-16.8x3.1x
Upside (Analyst Target)
-112.3%55.1%
Fair Value Upside
Unlock1.3%7.2%Unlock

Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells, as well as consist of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising kit medical devices, syringe kit, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
132.59K0.81%131.90K
Other Institutional Investors
2.51M15.41%2.50M
Public Companies & Retail Investors
13.66M83.78%13.59M
Total
16.3M100.00%16.22M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Extended Market ETF0.28%46,14749
Fidelity Concord Street Trust - Fidelity Extended Market Index Fund0.15%23,82025

People Also Watch

10.990
AIXI
-3.00%
9.125
ONDS
-5.93%
4.0100
BIRD
-0.25%
1.7500
ELAB
-6.91%
13.07
POET
-8.02%

FAQ

What Is the Quince Therapeutics (QNCX) Stock Price Today?

The Quince Therapeutics stock price today is 1.070 USD.

What Stock Exchange Does Quince Therapeutics Trade On?

Quince Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Quince Therapeutics?

The stock symbol for Quince Therapeutics is "QNCX."

What Is the Quince Therapeutics Market Cap?

As of today, Quince Therapeutics market cap is 17.360M USD.

What Is Quince Therapeutics's Earnings Per Share (TTM)?

The Quince Therapeutics EPS (TTM) is -6.862.

When Is the Next Quince Therapeutics Earnings Date?

Quince Therapeutics will release its next earnings report on Aug 11, 2026.

From a Technical Analysis Perspective, Is QNCX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Quince Therapeutics Stock Split?

Quince Therapeutics has split 1 times.

How Many Employees Does Quince Therapeutics Have?

Quince Therapeutics has 38 employees.

What is the current trading status of Quince Therapeutics (QNCX)?

As of May 20, 2026, Quince Therapeutics (QNCX) is trading at a price of 1.070 USD, with a previous close of 0.995 USD. The stock has fluctuated within a day range of 0.960 USD to 1.110 USD, while its 52-week range spans from 0.790 USD to 45.499 USD.

What Is the QNCX Premarket Price?

QNCX's last pre-market stock price is 1.020 USD. The pre-market share volume is 210,700.000, and the stock has decreased by 0.025, or 2.530%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.